Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL): Results From a Pivotal Phase 2 Clinical Trial

類似資料

• OR25-07 A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety
  著者:: Jimenez, Camilo, 等
  出版事項: (2020)
• Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
  著者:: Pryma, Daniel A., 等
  出版事項: (2019)
• SUN-345 Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA(®)) in Patients with Iobenguane Scan Positive Cancers
  著者:: Jimenez, Camilo, 等
  出版事項: (2019)
• External Beam Radiation Therapy (EBRT) for Patients with Malignant Pheochromocytoma and Non-Head and Neck Paraganglioma: Combination with (131)I-MIBG
  著者:: Fishbein, Lauren, 等
  出版事項: (2012)
• High-specific-activity (131)I-MIBG vs (177)Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma
  著者:: Jha, Abhishek, 等
  出版事項: (2021)